Inherited risk factors for venous thromboembolism: Implications for clinical practice

Anderson, 1991, A population based perspective of the hospital incidence and case-fatality rates of deep-vein thrombosis and pulmonary embolism, Arch Intern Med, 151, 933, 10.1001/archinte.1991.00400050081016 Svensson, 1994, Resistance to activated protein C as a basis for venous thrombosis, N Engl J Med, 343, 1536 Koster, 1993, Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study, Lancet, 342, 1503, 10.1016/S0140-6736(05)80081-9 Ridker, 1997, Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening, JAMA, 277, 1305, 10.1001/jama.1997.03540400055031 Ridker, 1995, Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men, N Engl J Med, 332, 912, 10.1056/NEJM199504063321403 Simioni, 1997, The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden), N Engl J Med, 336, 399, 10.1056/NEJM199702063360602 Ridker, 1995, Factor V Leiden and risks of recurrent idiopathic venous thromboembolism, Circulation, 92, 2800, 10.1161/01.CIR.92.10.2800 Price, 1997, Factor V Leiden mutation and the risks of thromboembolic disease: a clinical perspective, Ann Intern Med, 127, 895, 10.7326/0003-4819-127-10-199711150-00007 Vandenbroucke, 1994, Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation, Lancet, 344, 1453, 10.1016/S0140-6736(94)90286-0 Ridker, 1997, Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risks of future venous thromboem bolism, Circulation, 95, 1777, 10.1161/01.CIR.95.7.1777 Ridker, 1998, Factor V Leiden mutation as a risk factor for recurrent pregnancy loss, Ann Intern Med, 128, 1000, 10.7326/0003-4819-128-12_Part_1-199806150-00007 Poort, 1996, A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood, 88, 3698, 10.1182/blood.V88.10.3698.bloodjournal88103698 Ridker, 1999, G20210A mutation in the prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men, Circulation, 99, 999, 10.1161/01.CIR.99.8.999 De Stefano, 1999, The risk of recurrent deep vein thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation, N Engl J Med, 341, 801, 10.1056/NEJM199909093411104 Ray, 1998, Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease, Arch Intern Med, 158, 2101, 10.1001/archinte.158.19.2101 Rosendaal, 1993, Venous thrombosis: a multicausal disease, Lancet, 353, 1167, 10.1016/S0140-6736(98)10266-0 Schulman, 1995, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism, N Engl J Med, 332, 1661, 10.1056/NEJM199506223322501 Schulman, 1997, The duration of oral anticoagulant therapy after a second episode of venous thromboembolism, N Engl J Med, 336, 393, 10.1056/NEJM199702063360601 Kearon, 1999, A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous throm boembolism, N Engl J Med, 340, 901, 10.1056/NEJM199903253401201 Ridker, 1998, Longterm, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembohsm (PREVENT) trial, Vasc Med Rev, 3, 67, 10.1177/1358836X9800300114